Centrient Pharmaceuticals Receives Warning Letter for Indian Plant

Centrient Pharmaceuticals’ active pharmaceutical ingredient (API) facility in Punjab, India, received a warning letter from the FDA for multiple deficiencies including lax records, test validations and inadequate contaminant controls.
Source: Drug Industry Daily